8-K: Abeona Therapeutics Announces 2023 Financial Results and FDA Inspection Completion

Abeona Therapeutics reported its full year 2023 financial results and announced the completion of FDA inspections for its pz-cel manufacturing facility and clinical trial sites.

Summary

• Abeona Therapeutics has released its financial results for the full year 2023, showing a net loss of $54.2 million, or $2.53 per share.
• The company's cash, cash equivalents, and short-term investments totaled $52.6 million as of December 31, 2023, which is similar to the $52.5 million reported at the end of 2022.
• Net cash used in operating activities was $37.0 million for 2023, compared to $43.5 million in 2022.
• Abeona secured a $50 million credit facility, with $20 million funded in January 2024, to support commercialization efforts.
• The company estimates its current resources will fund operations into the first quarter of 2025, before any potential revenue from pz-cel sales or a Priority Review Voucher.
• License and other revenues for 2023 were $3.5 million, up from $1.4 million in 2022, primarily from clinical milestone payments.
• Research and development expenses increased to $31.1 million in 2023 from $29.0 million in 2022, due to increased BLA activities.
• General and administrative expenses rose to $19.0 million in 2023 from $17.3 million in 2022, mainly due to increased headcount for the potential pz-cel launch.
• The FDA completed a Pre-License Inspection (PLI) of Abeona's Cleveland manufacturing facility, issuing a Form 483 with observations related to process controls, which the company has responded to.
• The FDA also completed clinical study site inspections with no Form 483 observations noted.
• The target PDUFA date for the pz-cel BLA is May 25, 2024, and the FDA does not plan to hold an Advisory Committee meeting.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the progress with FDA inspections and the credit facility, but tempered by the net loss and the Form 483 observations. The company is making progress but faces risks.

Positives

• Abeona secured a $50 million credit facility to support commercialization efforts.
• The FDA completed clinical study site inspections with no observations noted.
• The FDA does not plan to convene an Advisory Committee meeting for the pz-cel application.
• Abeona's cash position remained relatively stable year-over-year.
• License and other revenues increased to $3.5 million in 2023.
• The company has submitted a response to the FDA regarding the Form 483 observations.
• The company is actively preparing for the potential U.S. commercial launch of pz-cel.
• The FDA has granted Priority Review for the pz-cel BLA.

Negatives

• Abeona reported a net loss of $54.2 million for 2023.
• The FDA issued a Form 483 with observations related to process controls at the manufacturing facility.
• Research and development expenses increased to $31.1 million in 2023.
• General and administrative expenses rose to $19.0 million in 2023.
• The company's cash runway is estimated to last until the first quarter of 2025, before any potential revenue from pz-cel sales.

Risks

• The FDA's review of the pz-cel BLA is ongoing, and approval is not guaranteed.
• The company's response to the FDA's Form 483 observations may not be sufficient to resolve all concerns.
• The company's cash runway is limited, and additional funding may be required if pz-cel is not approved or commercialized successfully.
• The company's ability to successfully launch and commercialize pz-cel is subject to market conditions and competition.
• The company's financial performance is dependent on the success of its pipeline and commercialization efforts.

Future Outlook

Abeona estimates that its current cash and credit facility are sufficient to fund operations into the first quarter of 2025, before accounting for any revenue from commercial sales of pz-cel or proceeds from the sale of a Priority Review Voucher.

Management Comments

• We appreciate the FDAs collaborative conduct of the PLI, and look forward to working with them through the remainder of the BLA review, said Vish Seshadri, Chief Executive Officer of Abeona.

Industry Context

This announcement is significant for the gene therapy sector, as it highlights the regulatory hurdles and financial challenges faced by companies developing novel therapies. The completion of FDA inspections and the upcoming PDUFA date for pz-cel are key milestones for Abeona and the broader RDEB treatment landscape.

Comparison to Industry Standards

• Abeona's cash burn of $37 million in 2023 is relatively high for a company of its size, but is not unusual for a clinical-stage biotech company preparing for a potential product launch.
• The increase in R&D and G&A expenses is consistent with the company's focus on advancing pz-cel through the regulatory process and preparing for commercialization.
• The $50 million credit facility is a common financing strategy for biotech companies in the lead up to a potential product launch.
• The FDA's issuance of a Form 483 is not uncommon during manufacturing inspections, and the company's response will be critical for the BLA review process.
• Companies like Krystal Biotech, which also focuses on RDEB treatments, have faced similar regulatory and commercialization challenges, making Abeona's progress closely watched by investors and the industry.

Stakeholder Impact

• Shareholders will be impacted by the financial results and the progress of the pz-cel BLA.
• Employees are impacted by the company's financial performance and the potential commercial launch of pz-cel.
• Patients with RDEB and their families are impacted by the potential approval of pz-cel.
• Creditors are impacted by the company's financial performance and the terms of the credit facility.

Next Steps

• Abeona will continue to work with the FDA to address the Form 483 observations.
• The company will continue to advance commercial activities in preparation for a potential U.S. launch of pz-cel.
• The FDA's review of the pz-cel BLA is ongoing, with a target PDUFA date of May 25, 2024.

Key Dates

Keywords

Abeona Therapeutics, pz-cel, RDEB, FDA, Biologics License Application, manufacturing, clinical trials, financial results, gene therapy, credit facility